Antithrombin III in Patients Admitted to Intensive Care Units: a Multicenter Observational Study

Overview

Journal Crit Care

Specialty Critical Care

Date 2002 Oct 26

PMID 12398786

Citations 3

Authors

Andrea Messori

Franca Vacca

Monica Vaiani

Sabrina Trippoli

Affiliations

Soon will be listed here.

Abstract

Introduction: The administration of antithrombin III (ATIII) is useful in patients with congenital deficiency, but evidence for the other therapeutic indications of this drug is still uncertain. In Italy, the use of ATIII is very common in intensive care units (ICUs). For this reason we undertook an observational study to determine the pattern of use of ATIII in ICUs and to assess the outcome of patients given this treatment.

Methods: From 20 May to 20 July 2001 all consecutive patients admitted to ICUs in 20 Italian hospitals and treated with ATIII were enrolled. The following information was recorded from each patient: congenital deficiency, indication for use of ATIII, daily dose and duration of ATIII treatment, outcome of hospitalization (alive or dead). The outcome data of our observational study were compared with those reported in previously published randomized controlled trials (RCTs).

Results: Two hundred and sixteen patients were enrolled in the study. The clinical indications for using ATIII were sepsis (25.9%), disseminated intravascular coagulation (23.1%), and other clinical conditions (46.8%). At the end of the study, 65.3% of the patients were alive, 24.5% died and 10.2% were still in the hospital. Among the patients with sepsis (n = 56), 19 died during the observation period (33.9%; 95% confidence interval 22.1-47.5%).

Discussion: Our study described the pattern of use of ATIII in Italian hospitals and provided information on the outcome of the subgroup treated with sepsis. A meta-analysis of current data from RCTs, together with our findings, indicates that there is no sound basis for using this drug in ICU patients with sepsis.

Citing Articles

Clinical Scenarios for Discordant Anti-Xa.

Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, Teng T, Jan R, Mok M Adv Hematol. 2016; 2016:4054806.

PMID: 27293440 PMC: 4880685. DOI: 10.1155/2016/4054806.

Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G Blood Transfus. 2009; 7(4):325-34.

PMID: 20011645 PMC: 2782811. DOI: 10.2450/2009.0116-09.

The limitations of observational studies on the treatment of severe sepsis.

Wiedermann C Crit Care. 2003; 6(6):546-7; author reply 548.

PMID: 12512505 PMC: 153444. DOI: 10.1186/cc1838.

References

Benson K, Hartz A . A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000; 342(25):1878-86. DOI: 10.1056/NEJM200006223422506. View

Concato J, Shah N, Horwitz R . Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342(25):1887-92. PMC: 1557642. DOI: 10.1056/NEJM200006223422507. View

Pocock S, Elbourne D . Randomized trials or observational tribulations?. N Engl J Med. 2000; 342(25):1907-9. DOI: 10.1056/NEJM200006223422511. View

Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A . Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000; 321(7269):1103-6. PMC: 27516. DOI: 10.1136/bmj.321.7269.1103. View

Warren B, Eid A, Singer P, Pillay S, Carl P, Novak I . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286(15):1869-78. DOI: 10.1001/jama.286.15.1869. View

Mannucci P, Boyer C, Wolf M, Tripodi A, LARRIEU M . Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol. 1982; 50(3):531-5. DOI: 10.1111/j.1365-2141.1982.tb01949.x. View

Hellgren M, Tengborn L, Abildgaard U . Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982; 14(2):127-41. DOI: 10.1159/000299460. View

WINTER J, Fenech A, Ridley W, Bennett B, Cumming A, Mackie M . Familial antithrombin III deficiency. Q J Med. 1982; 51(204):373-95. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

De Stefano V, Leone G, De Carolis S, Ferrelli R, Di Donfrancesco A, Moneta E . Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost. 1988; 59(2):193-6. View

11.

Schwartz R, Bauer K, Rosenberg R, Kavanaugh E, Davies D, Bogdanoff D . Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med. 1989; 87(3B):53S-60S. DOI: 10.1016/0002-9343(89)80533-9. View

12.

Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J . Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993; 104(3):882-8. DOI: 10.1378/chest.104.3.882. View

13.

Lechner K, Kyrle P . Antithrombin III concentrates--are they clinically useful?. Thromb Haemost. 1995; 73(3):340-8. View

14.

Baudo F, Caimi T, de Cataldo F, Ravizza A, Arlati S, Casella G . Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998; 24(4):336-42. DOI: 10.1007/s001340050576. View

15.

Eisele B, Lamy M, Thijs L, Keinecke H, Schuster H, Matthias F . Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998; 24(7):663-72. DOI: 10.1007/s001340050642. View